Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0.25% vs 0.5% Bupivacaine FNB for ACL Reconstruction
NCT01593566Phase 4
Key facts
- Status
- Completed
- Start
- Apr 2011
- Primary completion
- Apr 2013
- Countries
- 1
- Sponsor
- Mahidol University
- Modality
- Small Molecules
- Drugs
- bupivacaine
- Conditions
- postoperative pain
01
Overview
Phase 4, randomised, single-blind trial of bupivacaine in postoperative pain (2 arms), sponsored by Mahidol University. Primary endpoint: Time to first analgesic requirement at 48 hours. Started Apr 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedSingle-blind
0.25% bupivacaine
Femoral nerve block using 0.25% bupivacaine
0.5% bupivacaine
Femoral nerve block using 0.5% bupivacaine
03
Who it enrols
Patients scheduled for ACL reconstruction with ASA I-II and body weight >= 50 kg.
04
Endpoints
Primary
Time to first analgesic requirement
Secondary
Pain score scale
Beyond the preview
Go deeper on NCT01593566.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593566.